Insulinoma - The incremental value of somatostatin receptor positron emission tomography

Sir,

The clinical diagnosis of hyperinsulinemic hypoglycemia is by itself difficult and most patients have a delayed diagnosis.\(^1\) In an adult, nondiabetic patient, insulinoma is the most common cause of hyperinsulinemic hypoglycemia. Furthermore, about 10% of insulinomas are believed to have already metastasized by the time they are diagnosed. Conventional imaging techniques such as computed tomography (CT) and magnetic resonance imaging (MRI) may not always be able to localize the lesions leading to further delay in definitive treatment that is surgical excision.\(^2,3\) Functional imaging has played an important role in lesion localization. Octreotide-based tracers such as \(^{111}\)In-diethylenetriaminepentaacetic acid-octreotide for planar and single-photon emission computed tomography imaging were initially evaluated.\(^4\) These were followed up with positron emission tomography (PET)-based tracers such as \(^{68}\)Ga-DOTA-TOC/NOC and more recently \(^{68}\)Ga-DATA-TOC.\(^5,6\) Most recently, \(^{68}\)Ga-exendin has emerged as promising PET tracer in insulinoma imaging.\(^7,8\) The definitive therapy for insulinoma is surgery, and localization of the tumor before surgery is important for planning the type of surgery. Although lymphadenectomy is not performed in insulinoma surgery, preoperative nodal positivity in imaging may help to plan lymphadenectomy and accurate pathological staging, especially in malignant insulinomas.\(^2\)

Here, we present the incremental benefit of \(^{68}\)Ga-DOTA-NOC PET/CT in the localization of an insulinoma in a 23-year-old young female patient who presented with symptoms of weight gain, menstrual irregularities, and hirsutism for last 3 years. She was started on medications for polycystic ovary syndrome. Few months after starting treatment, she developed giddiness, especially after exertion and minimal fasting. She developed two episodes of seizures about 2 years back with tonic–clonic movements of all four limbs and postictal confusion for about 30 min. She was evaluated by a neurologist. MRI of the brain and cerebrospinal fluid studies were normal. She was started on antiepileptic medication (phenytoin). She underwent multiple blood investigations which all returned inconclusive. An endocrine opinion was sought, and she

**Figure 1:** (a) \(^{68}\)Ga-DOTA-NOC PET/CT maximum intensity projection image showing physiological distribution and no overt focus of abnormal localization. (b) Transaxial contrast-enhanced computed tomography showing bulky tail of pancreas but no definite enhancing lesion. (c) Transaxial noncontrast computed tomography showing bulky tail of pancreas but no definite lesion. (d) \(^{68}\)Ga-DOTA-NOC PET/CT transaxial slice at the level of pancreas showing intense uptake of tracer in the tail with a discrete lesion proximal to it - ?node. (e) \(^{68}\)Ga-DOTA-NOC PET/CT transaxial slice at the level of pancreas showing two other distinct foci of intense uptake corresponding to rounded nodular lesions near the primary - consistent with peripancreatic nodes
was admitted for evaluation. Her fasting blood glucose as low as 24 mg%. She underwent contrast-enhanced CT (CECT) of the abdomen which was reported as normal. She was referred to our hospital where an in-house evaluation showed a fasting glucose level of 30 mg%, C-peptide - 6.56 (1.1–4.4 ng/ml), and insulin 81.9 µU/ml (2–25 µU/ml). A review of the CECT showed a bulky tail of pancreas. She also underwent 68Ga-DOTA-NOC PET/CT which showed a 3.1 cm × 2.6 cm soft tissue density mass lesion in the tail of pancreas and few peripancreatic lymph nodes with increased radiotracer uptake indicating somatostatin receptor expression [Figure 1]. Rest of the pancreas was normal. With these imaging findings, she was referred to the surgeon and she underwent distal pancreatectomy and splenectomy.

The patient has no hypoglycemic spells postoperatively, with rebound hyperglycemia in the immediate postoperative period. Histopathology revealed a Grade 2 neuroendocrine tumor with a mitotic count of 4–6/10 HPF and Ki-67 labeling index of 6%–7%. Six peripancreatic nodes were found to have metastatic tumor deposits.

Octreotide imaging has been shown to have a variable sensitivity in the detection of insulinomas about 25% for octreoscan and recently 84.6% for octreotide PET/CT.[5,9] In our case, not only did the octreotide PET/CT identify the pancreatic primary but also correctly demonstrated the metastatic nodes, which could be appropriately resected.

It is, therefore, important for the endocrinologist to ask for an early octreotide PET/CT in cases of suspected pancreatogenic hyperinsulinemic hypoglycemia.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

S. T. Arunraj, Nishikant Avinash Damle, Chandrasekhar Bal, Yashdeep Gupta1, Sujoy Pal2

Departments of Nuclear Medicine, 1Endocrinology and 2Gastrointestinal Surgery, All India Institute of Medical Sciences, New Delhi, India

REFERENCES

1. Ma H, Zhang XP, Zhang Y, Lu HD, Wang JT, Zhang Y, et al. Pancreatic insulinoma misdiagnosed as epilepsy for eight years: A case report and literature review. Intern Med 2015;54:1519-22.
2. Okabayashi T, Shima Y, Sumiyoshi T, Kozuki A, Ito S, Ogawa Y, et al. Diagnosis and management of insulinoma. World J Gastroenterol 2013;19:829-37.
3. Chiruvella A, Kooby DA. Surgical management of pancreatic neuroendocrine tumors. Surg Oncol Clin N Am 2016;25:401-21.
4. Virgolini I, Traub-Weidinger T, Decristoforo C. Nuclear medicine in the detection and management of pancreatic islet-cell tumours. Best Pract Res Clin Endocrinol Metab 2005;19:213-27.
5. Prasad V, Sainz-Esteban A, Arsenic R, Plockinger U, Denecke T, Pape UF, et al. Role of (68)Ga somatostatin receptor PET/CT in the detection of endogenous hyperinsulinemic focus: An explorative study. Eur J Nucl Med Mol Imaging 2016;43:1593-600.
6. Seemann J, Waldron B, Parker D, Roesch F. DATATOC: A novel conjugate for kit-type (68)Ga labelling of TOC at ambient temperature. EJNMMI Radiopharm Chem 2016;1:4.
7. Antwi K, Fani M, Nicolas G, Rottenburger C, Heye T, Reubi JC, et al. Localization of hidden insulinomas with 68Ga-DOTA-Exendin-4 PET:CT. A pilot study. J Nucl Med 2015;56:1075-8.
8. Luo Y, Pan Q, Yao S, Yu M, Wu W, Xue H, et al. Glucagon-like peptide-1 receptor PET/CT with 68Ga-NOTA-Exendin-4 for detecting localized insulinoma: A prospective cohort study. J Nucl Med 2016;57:715-20.
9. Vezzosi D, Bennet A, Rochaix P, Courbon F, Selves J, Pradere B, et al. Octreotide in insulinoma patients: Efficacy on hypoglycemia, relationships with octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. Eur J Endocrinol 2005;152:757-67.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

Access this online article

Quick Response Code: 10.4103/2230-6849.168012
Website: www.ijem.in
DOI: 10.4103/2230-6849.168012

Cite this article as: Arunraj ST, Damle NA, Bal C, Gupta Y, Pal S. Insulinoma - The incremental value of somatostatin receptor positron emission tomography. Indian J Endocr Metab 2017;21:255-6.